I think you need to acknowledge that CER was an anomaly and you probably anchor too much weight to this situation as a repeatable or likely one for other stocks. I dont disagree that MSB could go a similar way necessarily but if you are chasing a repeat of CER I can only recommend taming your expectations here. best chance for a "short term" turnaround, outside of a partnership is if the FDA are accepting of their new potency assay data and an approval for the paediatrics.
Ann: MSB Launches Entitlement Offer and Placement, page-111
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |